Research
Hormonal
GLP-1 receptor agonists and dual receptor agonists effectively counteract hyperglycemia and obesity.
These medications may be prioritized in treatment plans for T2D patients with obesity.
StrongSupportsmedium confidence
GLP-1 RAs and the new class of GLP1 and gastric inhibitory polypeptide dual RAs counteract 2 of these metabolic defects of T2D, hyperglycemia and obesity.
Why this rating
The abstract provides a strong basis for the claims about these medications.
Source
New Horizons: Emerging Antidiabetic Medications
Geltrude Mingrone et al. · The Journal of Clinical Endocrinology & Metabolism · 2022
DOI 10.1210/clinem/dgac499
reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →